A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial is in Phase 1/2, which means it's still working out safety and the right dose — given that my lymphoma has already come back or stopped responding to treatment, does the potential benefit of trying an investigational CAR-T therapy like GLPG5101 outweigh the risks at this stage, compared to other options I might still have?
2. 2Since Phase 1 of this trial is specifically tracking serious adverse events and dose-limiting toxicities, what kinds of side effects have been seen so far, and how would those be managed if I were to experience them?
3. 3The trial is listed as 'active, not recruiting,' which suggests they've stopped enrolling new patients — is there any chance I could still be considered, or is there a similar or follow-on study I should be looking into instead?
4. 4This trial appears to include several different subtypes of B-cell Non-Hodgkin Lymphoma in separate cohorts — do you know which cohort would apply to my specific diagnosis, and does that affect what outcomes they're measuring or what the treatment approach looks like?
5. 5Phase 2 of this trial is measuring whether patients have an objective response using established lymphoma criteria — based on what's been reported so far, do you have a sense of how GLPG5101 is performing compared to standard salvage therapies or other CAR-T options available to me right now?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.